Business Wire

Tishomingo Connect expands fiber network into rural Mississippi with Adtran Mosaic One

5.9.2024 14:00:00 CEST | Business Wire | Press release

Share

News summary: Service provider required scalable fiber access technology to give more underserved customers access to reliable, high-speed internet Adtran’s Mosaic One and 10G fiber access platform enable Tishomingo Connect to scale its network rapidly and efficiently Deployment expands broadband access across rural Mississippi, supporting national efforts to close the digital divide

Adtrantoday announced that Tishomingo Connect, a subsidiary of Tishomingo County Electric Power Association (TCEPA), has deployed its Mosaic One SaaS solution to enhance rural broadband access. Leveraging Adtran’s full suite of fiber-to-the-premises and home networking technologies, Tishomingo Connect is ensuring more households and businesses can benefit from its broadband service. With Adtran’s scalable and programmable fiber access technology, the service provider can maximize its existing network investment as it expands its service area to meet the growing demand for fast and reliable internet in Northeast Mississippi. Adtran’s partner LogicomUSA is also playing a key role in the development and deployment of the new broadband network, providing technical support and ongoing NOC services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905594150/en/

Adtran’s technology is helping Tishomingo Connect deliver high-speed broadband to underserved regions of rural Mississippi. (Photo: Business Wire)

“Fiber broadband revitalizes communities and transforms lives by increasing economic activity and enabling access to services such as telehealth. That’s why we’re determined to extend the reach of our fiber network to ensure that more households and businesses in rural areas can enjoy the same high-quality broadband as those in other parts of the state,” said Cody Durham, CEO and GM of Tishomingo Connect. “By deploying Adtran’s fiber broadband technology and harnessing the support offered by its expert team, we’re expanding our network rapidly to give communities the connectivity they deserve. What’s more, with Mosaic One, we can deliver a more efficient, consistent and reliable service for all our members.”

Tishomingo Connect’s strategic investment in Adtran’s high-capacity fiber access platform ensures they can leverage extra capacity as data demand rises. With Adtran’s scalable XGS-PON OLTs and SDX Series optical network terminals, offering up to 10Gbit/s symmetrical data rates, network expansion is seamless and rapid. Additionally, Adtran’s SDG 800 Series service delivery gateways deliver high-speed Wi-Fi 6 performance, guaranteeing robust connectivity for an increasing number of household devices. Mosaic One further empowers Tishomingo Connect with actionable intelligence, enhancing subscriber experience and optimizing operations through a comprehensive view of customer interactions. AI-driven insights enable timely maintenance and reduce service disruptions, improving network reliability and cutting operating costs.

“Adtran is proud to be a partner of Tishomingo Connect as it continues its vital work of bringing fiber broadband to its members living in underserved regions of rural Mississippi,” commented John Scherzinger, GM of Americas sales at Adtran. “We have a deep understanding of the challenges and opportunities involved for electric utilities moving into the fiber broadband space. We also have the expertise, experience and technology to ensure these crucially important high-capacity rural networks are built in the most cost-effective way possible. With our Mosaic One and multigigabit fiber access solutions, Tishomingo has a seamless and cost-effective upgrade path to offering even more capable services in the future.”

“We support the work of electric cooperative subsidiaries like Tishomingo Connect to increase broadband connectivity in regions long overlooked by other service providers. That’s why we’re proud to offer a range of value-added services that ensure more rural subscribers can take advantage of a fast and reliable internet connection,” noted Noah Southerland, CEO of LogicomUSA. “Our technology and comprehensive support services are designed to minimize costs and time without compromising quality. This makes it easier for Tishomingo Connect to deploy and manage its broadband network, and it also means end-users benefit from high-quality connectivity they can always rely on.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by 
ADTRAN Holdings, Inc. 
www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240905594150/en/

Contacts

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye